FERRING B.V.

FERRING B.V. Overview

Company Headquarters: Saint-Prex, Switzerland

Founded: 1950

Workforce: 6500+

Company Working:

Ferring B.V. engages in the R&D, manufacturing, and marketing of a wide range of drugs for osteoarthritis, endocrinology, gastroenterology, urology, obstetrics, and infertility. It provides products and services to private laboratories, clinics, physicians’ offices, and hospitals and critical care centers, through direct sales and a wide network of distributors across the world. It has production centers in 11 countries, including Argentina, the Czech Republic, Denmark, China, Israel, Germany, Mexico, Scotland, and Switzerland. It has R&D centers in China, Denmark, Israel, India, Scotland, Switzerland, and the US. Ferring B.V. has its working subsidiaries in almost 60 nations and markets its treatments in 110 international locations.

Strategy

Ferring focuses to divest activities in some business areas and to strengthen others through portfolio measures, including mergers and acquisitions. Technology and innovations are designed to meet the demand for the requirements of patients with treatment options. It focuses on investing in innovative technology platforms for creating new solutions for patients in their core areas of reproductive medicine and women’s health, gastroenterology, and urology.

Company Snapshot

6,500

Employees

1950

Founded

Saint-Prex, Switzerland

Headquarters

SWOT Analysis

Strengths

Strong presence all over the world
Diverse product portfolio
Strong brand image
Innovative products
Strong distribution network
Well established research & development

Weaknesses

Product recalls hampering the company’s growth
Increased production costs
Low presence in outside Europe
Limited products related to the market

Opportunities

Expanding the innovation map beyond the established product portfolio
Mergers and acquisitions
Opportunities to tap emerging markets
Merger and acquisitions to expand the portfolio

Threats

Demand for products may not increase due to economic conditions
Competition from global players
Changing competitive environment

Key Developments

Date	Approach	Development
January 2019	Agreement	Ferring has agreed on terms to acquire the US commercialization rights to produce the Ganirelix Acetate Injection. This injectable therapy is used to prevent premature luteinizing hormone flows in women who are undergoing fertility treatment.
February 2018	Expansion	Ferring announced the expansion of its capabilities in biologics through the new biotech center installed at the company’s manufacturing site in St-Prex, Switzerland. In addition to the development and manufacture of new biologics, the API for REKOVELLE (for fertility treatment) is also to be manufactured at the new center.
June 2014	Collaboration	Ferring B.V. entered into a collaboration with Roche (Basel, Switzerland), a pioneer in pharmaceuticals and diagnostics, to develop personalized infertility treatment. The collaboration aimed at the combination of diagnostic testing technology from Roche with Ferring’s human cell line-derived recombinant follicle-stimulating hormone (human rFSH), a gonadotropin that was in phase III development.

Product Offering

FERRING B.V.
- MENOPUR (menotropins for injection)
- ENDOMETRIN (progesterone) Vaginal Insert
- NOVAREL (chorionic gonadotropin for injection, USP)
- BRAVELLE (uFSH)
- CHORAGON (u-HOG)
- GONAPETYL (triptorelin acetate)
- LUTINUS (progesterone)
- LUTREPULSE (gonadorelin acetate)
- MISODEL (misoprostol vaginal insert)
- NORPROLAC (quinagolide hydrochloride)
- REKOVELLE (follitropin delta)
- Orthopedics

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.